Combined Levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma a phase II study

Edward T. Creagan, Robert D. Hestorff, Vera Jean Suman, James A. Mailliard, Suresh Nair, James E. Krook, John W. Kugler, Robert F. Marschke, John C. Michalak, Loren K. Tschetter

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Adoptive immunotherapy (AI) with interleukin-2 (IL-2) and lymphokine- activated killer (LAK) cells is an antineoplastic modality in which immune- activated cells are administered to a host having cancer in an attempt to mediate tumor regression. Levamisole (LEV), an immune stimulant, has been suggested as having therapeutic effectiveness in a variety of cancers. After a phase I trial of recombinant IL-2 plus LEV, a phase II trial of this combination was conducted in patients who had advanced renal cell carcinoma. The regimen was IL-2 at 3 x 106 U/m2 daily x 5 plus LEV at 50 mg/m2 perorally three times a day x 5. Only one of the 22 eligible patients had a regression. It was a partial regression, 85 days in duration. The median time to treatment failure (refusal, progression, or off study because of toxicity) was 36 days. The only grade 4 toxicity reported was lethargy. This regimen is not recommended for further testing in patients who have advanced renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)139-141
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume21
Issue number2
DOIs
StatePublished - Apr 1998

Fingerprint

Levamisole
Renal Cell Carcinoma
Interleukin-2
Treatment Refusal
Adoptive Immunotherapy
Lymphokine-Activated Killer Cells
Neoplasms
Lethargy
Treatment Failure
Antineoplastic Agents
Therapeutics

Keywords

  • Interleukin-2
  • Renal cell cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combined Levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma a phase II study. / Creagan, Edward T.; Hestorff, Robert D.; Suman, Vera Jean; Mailliard, James A.; Nair, Suresh; Krook, James E.; Kugler, John W.; Marschke, Robert F.; Michalak, John C.; Tschetter, Loren K.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 21, No. 2, 04.1998, p. 139-141.

Research output: Contribution to journalArticle

Creagan, Edward T. ; Hestorff, Robert D. ; Suman, Vera Jean ; Mailliard, James A. ; Nair, Suresh ; Krook, James E. ; Kugler, John W. ; Marschke, Robert F. ; Michalak, John C. ; Tschetter, Loren K. / Combined Levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma a phase II study. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1998 ; Vol. 21, No. 2. pp. 139-141.
@article{817a1686cd2e4a14a49e1a036ce32bbe,
title = "Combined Levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma a phase II study",
abstract = "Adoptive immunotherapy (AI) with interleukin-2 (IL-2) and lymphokine- activated killer (LAK) cells is an antineoplastic modality in which immune- activated cells are administered to a host having cancer in an attempt to mediate tumor regression. Levamisole (LEV), an immune stimulant, has been suggested as having therapeutic effectiveness in a variety of cancers. After a phase I trial of recombinant IL-2 plus LEV, a phase II trial of this combination was conducted in patients who had advanced renal cell carcinoma. The regimen was IL-2 at 3 x 106 U/m2 daily x 5 plus LEV at 50 mg/m2 perorally three times a day x 5. Only one of the 22 eligible patients had a regression. It was a partial regression, 85 days in duration. The median time to treatment failure (refusal, progression, or off study because of toxicity) was 36 days. The only grade 4 toxicity reported was lethargy. This regimen is not recommended for further testing in patients who have advanced renal cell carcinoma.",
keywords = "Interleukin-2, Renal cell cancer",
author = "Creagan, {Edward T.} and Hestorff, {Robert D.} and Suman, {Vera Jean} and Mailliard, {James A.} and Suresh Nair and Krook, {James E.} and Kugler, {John W.} and Marschke, {Robert F.} and Michalak, {John C.} and Tschetter, {Loren K.}",
year = "1998",
month = "4",
doi = "10.1097/00000421-199804000-00008",
language = "English (US)",
volume = "21",
pages = "139--141",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Combined Levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma a phase II study

AU - Creagan, Edward T.

AU - Hestorff, Robert D.

AU - Suman, Vera Jean

AU - Mailliard, James A.

AU - Nair, Suresh

AU - Krook, James E.

AU - Kugler, John W.

AU - Marschke, Robert F.

AU - Michalak, John C.

AU - Tschetter, Loren K.

PY - 1998/4

Y1 - 1998/4

N2 - Adoptive immunotherapy (AI) with interleukin-2 (IL-2) and lymphokine- activated killer (LAK) cells is an antineoplastic modality in which immune- activated cells are administered to a host having cancer in an attempt to mediate tumor regression. Levamisole (LEV), an immune stimulant, has been suggested as having therapeutic effectiveness in a variety of cancers. After a phase I trial of recombinant IL-2 plus LEV, a phase II trial of this combination was conducted in patients who had advanced renal cell carcinoma. The regimen was IL-2 at 3 x 106 U/m2 daily x 5 plus LEV at 50 mg/m2 perorally three times a day x 5. Only one of the 22 eligible patients had a regression. It was a partial regression, 85 days in duration. The median time to treatment failure (refusal, progression, or off study because of toxicity) was 36 days. The only grade 4 toxicity reported was lethargy. This regimen is not recommended for further testing in patients who have advanced renal cell carcinoma.

AB - Adoptive immunotherapy (AI) with interleukin-2 (IL-2) and lymphokine- activated killer (LAK) cells is an antineoplastic modality in which immune- activated cells are administered to a host having cancer in an attempt to mediate tumor regression. Levamisole (LEV), an immune stimulant, has been suggested as having therapeutic effectiveness in a variety of cancers. After a phase I trial of recombinant IL-2 plus LEV, a phase II trial of this combination was conducted in patients who had advanced renal cell carcinoma. The regimen was IL-2 at 3 x 106 U/m2 daily x 5 plus LEV at 50 mg/m2 perorally three times a day x 5. Only one of the 22 eligible patients had a regression. It was a partial regression, 85 days in duration. The median time to treatment failure (refusal, progression, or off study because of toxicity) was 36 days. The only grade 4 toxicity reported was lethargy. This regimen is not recommended for further testing in patients who have advanced renal cell carcinoma.

KW - Interleukin-2

KW - Renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=0031899690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031899690&partnerID=8YFLogxK

U2 - 10.1097/00000421-199804000-00008

DO - 10.1097/00000421-199804000-00008

M3 - Article

C2 - 9537198

AN - SCOPUS:0031899690

VL - 21

SP - 139

EP - 141

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 2

ER -